Certain of the representations of Taro are qualified by materiality or a material adverse effect
standard. For purposes of the merger agreement, “material adverse effect” means an effect, change, event or circumstance (each, an “Effect”) that, considered together with all other Effects, has a material adverse effect on:
(a) the business, assets, liabilities, condition (financial or otherwise), operations or results of operations of Taro and its subsidiaries taken as a whole; or (b) the ability of Taro to consummate the Transactions or to perform any of
its covenants or obligations under the merger agreement; provided, however, that certain matters are not taken into account in determining whether a material adverse effect has occurred: (i) changes in the economy or financial markets
(including credit markets) in general, (ii) changes in the economic, business, financial or regulatory environment generally affecting any of the industries in which Taro and its subsidiaries operate, (iii) changes in law or applicable
accounting regulations or principles or interpretations thereof, (iv) changes that arise out of the existence or announcement of the merger agreement or out of actions required by the Transactions, (v) acts of war, armed hostilities or
terrorism or any escalation or worsening of any acts of war, armed hostilities or terrorism (other than such acts of war, armed hostilities or terrorism, or escalation or worsening thereof, that cause any damage or destruction to, or render
physically unusable, any facility or property of Taro or any of its subsidiaries or otherwise disrupt in any material manner the business or operations of Taro or any of its material subsidiaries), (vi) any failure, in and of itself, of Taro to
achieve any projections, forecasts, estimates, plans, predictions, performance metrics or operating statistics (provided that the cause or basis for Taro’s failure to meet such projections, forecasts, estimates, plans, predictions, performance
metrics or operating statistics shall not be excluded from the determination of whether a material adverse effect has occurred) and (vii) any litigation arising from allegations of a breach of fiduciary duty or other violation of applicable law
relating to the Transactions, or the approval and adoption thereof; provided, however, that with respect to clauses (i), (ii) and (iii), solely to the extent that the impact of such change or effect is not disproportionately adverse in any material
respects to Taro and its subsidiaries taken as a whole compared to other companies in the same industry.
合并协议包含Sun Pharma实体的声明和保证，其中涉及：Sun Pharma实体的组织和资格; Sun Pharma实体签署、交付和执行合并协议、合并和合并协议预期的其他交易的权限;合并协议的约束性质;无需股东投票;充足的融资;披露;分享所有权
合并协议中的陈述和保证不容易概括，并且可能受到双方在谈判合并协议条款时
同意的重要限制和条件的约束。此外，某些陈述和保证可能受到与通常适用于向股东公开
披露的合同重要性标准不同的合同重要性标准的约束，或者可能被用于在各方之间分配风险而不是确定事实。请您仔细阅读合并协议中标题为
公司的声明和声明以及Sun Pharma、Alkaloida、TDC、SPH和Merger Sub的声明和声明的章节。””合并协议中包含的各方陈述和保证在合并完成时失效。
代理声明;附表13 E-3;股东
会议
Taro同意准备本委托书，并在特别委员会合理批准委托书内容的前提下，尽快将本委托书邮寄给Taro’的股东（前提是，如果适用，该日期应在SEC或其工作人员通知其对附表13 E-3（定义见下文）没有进一步评论的日期之后）。Taro还同意使本委托书符合适用于其的法律要求，为Sun Pharma提供合理的机会来审查和评论本委托书的草稿，并立即将委托书提交给SEC。双方同意共同准备与交易有关的附表13 E-3（以下简称附表13 E-3），并在附表13 E-3内容获得特别委员会合理批准的情况下，立即将附表13 E-3提交给美国证券交易委员会。”Taro同意在收到SEC就附表13 E-3提出的任何意见以及SEC就附表13 E-3提出的任何修订请求或其他信息时，尽快通知Sun Pharma，并同意向Sun提供
51
